cilostazol has been researched along with Arrhythmia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 7.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 3.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| "Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication." | 2.47 | Effects of cilostazol in the heart. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 1 |
| Ashihara, T | 1 |
| Kimura, H | 1 |
| Jo, H | 1 |
| Itoh, H | 1 |
| Yamamoto, T | 1 |
| Aizawa, Y | 1 |
| Horie, M | 1 |
| Kwon, BJ | 1 |
| Lee, SH | 1 |
| Kim, DB | 1 |
| Park, HJ | 1 |
| Jang, SW | 1 |
| Ihm, SH | 1 |
| Kim, HY | 1 |
| Seung, KB | 1 |
| Barta, J | 2 |
| Sanganalmath, SK | 2 |
| Kumamoto, H | 2 |
| Takeda, N | 2 |
| Edes, I | 1 |
| Dhalla, NS | 2 |
| Kanlop, N | 2 |
| Shinlapawittayatorn, K | 1 |
| Sungnoon, R | 1 |
| Weerateerangkul, P | 1 |
| Chattipakorn, S | 2 |
| Chattipakorn, N | 2 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Atarashi, H | 1 |
| Endoh, Y | 1 |
| Saitoh, H | 1 |
| Kishida, H | 1 |
| Hayakawa, H | 1 |
2 reviews available for cilostazol and Arrhythmia
| Article | Year |
|---|---|
Effects of cilostazol in the heart.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Heart Conduction System; Heart Failure; He | 2011 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
2 trials available for cilostazol and Arrhythmia
| Article | Year |
|---|---|
A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease.
Topics: Arrhythmias, Cardiac; Cilostazol; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting S | 2015 |
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Topics: Administration, Oral; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardi | 1998 |
4 other studies available for cilostazol and Arrhythmia
| Article | Year |
|---|---|
Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; C | 2014 |
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Coronary Occlusion; Cyclic AMP; D | 2008 |
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Electric Countershock; Female; He | 2010 |
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr | 2008 |